全文获取类型
收费全文 | 7290篇 |
免费 | 479篇 |
国内免费 | 17篇 |
专业分类
耳鼻咽喉 | 59篇 |
儿科学 | 251篇 |
妇产科学 | 196篇 |
基础医学 | 1056篇 |
口腔科学 | 645篇 |
临床医学 | 614篇 |
内科学 | 1393篇 |
皮肤病学 | 291篇 |
神经病学 | 501篇 |
特种医学 | 168篇 |
外科学 | 886篇 |
综合类 | 233篇 |
一般理论 | 5篇 |
预防医学 | 444篇 |
眼科学 | 220篇 |
药学 | 435篇 |
中国医学 | 19篇 |
肿瘤学 | 370篇 |
出版年
2023年 | 48篇 |
2022年 | 100篇 |
2021年 | 244篇 |
2020年 | 134篇 |
2019年 | 187篇 |
2018年 | 212篇 |
2017年 | 115篇 |
2016年 | 144篇 |
2015年 | 155篇 |
2014年 | 232篇 |
2013年 | 311篇 |
2012年 | 429篇 |
2011年 | 471篇 |
2010年 | 249篇 |
2009年 | 200篇 |
2008年 | 370篇 |
2007年 | 464篇 |
2006年 | 412篇 |
2005年 | 380篇 |
2004年 | 356篇 |
2003年 | 316篇 |
2002年 | 305篇 |
2001年 | 100篇 |
2000年 | 110篇 |
1999年 | 105篇 |
1998年 | 82篇 |
1997年 | 59篇 |
1996年 | 56篇 |
1995年 | 52篇 |
1994年 | 55篇 |
1993年 | 38篇 |
1992年 | 67篇 |
1991年 | 66篇 |
1990年 | 64篇 |
1989年 | 59篇 |
1988年 | 53篇 |
1987年 | 38篇 |
1986年 | 38篇 |
1985年 | 57篇 |
1984年 | 41篇 |
1983年 | 43篇 |
1982年 | 49篇 |
1981年 | 27篇 |
1980年 | 28篇 |
1979年 | 30篇 |
1978年 | 28篇 |
1976年 | 34篇 |
1975年 | 24篇 |
1971年 | 31篇 |
1912年 | 24篇 |
排序方式: 共有7786条查询结果,搜索用时 15 毫秒
61.
62.
63.
64.
Stephen P. Juraschek Edgar R. Miller III Beiwen Wu Karen White Jeanne Charleston Allan C. Gelber Sharan K. Rai Kathryn A. Carson Lawrence J. Appel Hyon K. Choi 《Nutrients》2021,13(2)
The Dietary Approaches to Stop Hypertension (DASH) diet reduces serum urate (SU); however, the impact of the DASH diet has not been previously evaluated among patients with gout. We conducted a randomized, controlled, crossover pilot study to test the effects of ~$105/week ($15/day) of dietitian-directed groceries (DDG), patterned after the DASH diet, on SU, compared with self-directed grocery shopping (SDG). Participants had gout and were not taking urate lowering therapy. Each intervention period lasted 4 weeks; crossover occurred without a washout period. The primary endpoint was SU. Compliance was assessed by end-of-period fasting spot urine potassium and sodium measurements and self-reported consumption of daily servings of fruit and vegetables. We randomized 43 participants (19% women, 49% black, mean age 59 years) with 100% follow-up. Mean baseline SU was 8.1 mg/dL (SD, 0.8). During Period 1, DDG lowered SU by 0.55 mg/dL (95% CI: 0.07, 1.04) compared to SDG by 0.0 mg/dL (95% CI: −0.44, 0.44). However, after crossover (Period 2), the SU difference between groups was the opposite: SDG reduced SU by −0.48 mg/dL (95% CI: −0.98, 0.01) compared to DDG by −0.05 mg/dL (95% CI: −0.48, 0.38; P for interaction by period = 0.11). Nevertheless, DDG improved self-reported intake of fruit and vegetables (3.1 servings/day; 95% CI: 1.5, 4.8) and significantly reduced total spot urine sodium excretion by 22 percentage points (95% CI: −34.0, −8.6). Though relatively small in scale, this pilot study suggests that dietitian-directed, DASH-patterned groceries may lower SU among gout patients not on urate-lowering drugs. However, behavior intervention crossover trials without a washout period are likely vulnerable to strong carryover effects. Definitive evaluation of the DASH diet as a treatment for gout will require a controlled feeding trial, ideally with a parallel-design. 相似文献
65.
Casey J. Whife Ann-Maree Vallence Dale W. Edgar Fiona M. Wood 《Burns : journal of the International Society for Burn Injuries》2021,47(2):327-337
ObjectiveNeuroplasticity is the capacity of the brain to change or adapt with experience: brain changes occur with use, disuse, and injury. Repetitive transcranial magnetic stimulation (rTMS) can be used to induce neuroplasticity in the human brain. Here, we examined rTMS-induced neuroplasticity in the primary motor cortex in burns survivors and controls without injury, and whether neuroplasticity is associated with functional recovery in burns survivors.MethodsSixteen burn injury survivors (total body surface area of burn injury <15%) and 13 non-injured control participants were tested. Repetitive TMS (specifically, spaced continuous theta-burst stimulation[cTBS]) was applied to induce neuroplasticity 6 and 12 weeks after injury in burn survivors and in two sessions separated by 6 weeks in controls. Motor evoked potentials (MEPs) elicited by single-pulse TMS were measured before and after rTMS to measure neuroplasticity. Burns survivors completed a functional assessment 12 weeks after injury.ResultsNon-injured controls showed decreased MEP amplitude 15?30 min after spaced cTBS in both experimental sessions. Burn survivors showed a smaller change in MEP amplitude after spaced cTBS compared to controls 6 weeks after burn injury but no difference compared to controls 12 weeks after burn injury. In burn survivors, there was a significant positive association between general health outcome (Short-Form Health Survey) and the change in MEP amplitude after spaced cTBS 12 weeks after injury (r=.73, p = .01).ConclusionsThe current findings suggest that burn survivors have a reduced capacity for neuroplasticity early in the recovery period (6 weeks after injury), which normalizes later in the recovery period (12 weeks after injury). Furthermore, the results provide preliminary evidence to suggest that burn survivors with normalized neuroplasticity 12 weeks after injury recover faster after burn injury. 相似文献
66.
Gustavo Martinez-Mier Pedro I. Moreno-Ley Luis F. Budar-Fernández Marco T. Méndez-López Carlos A. Allende-Castellanos Luis A. Jiménez-López Daniel A. Barrera-Amoros Edgar Aguilar-Sandoval Maritza De la Paz-Román Ernesto Soto-Miranda Yamilli Rivera-Sanchez Mónica Martínez-Maldonado 《Transplantation proceedings》2021,53(3):1005-1009
ContextThymoglobulin is used effectively as induction agent in kidney transplantation but the optimal dose is not well established.ObjectiveDemonstrate that low-dose thymoglobulin (3 mg/kg) has similar efficacy and safety compared to basiliximab induction in low-risk kidney transplantation under standard maintenance immunosuppressionDesign, Setting, ParticipantsProspective randomized study in kidney transplant patients (12/2016-05/2018). Inclusion criteria: Recipients > 18 years, first living donor transplant. Exclusion criteria: Second and multiorgan transplant, ABO incompatibility, positive cross-match, panel reactive antibodies (PRA) > 30%, positive donor-specific antibody, human immunodeficiency virus, hepatitis B surface antigen, hepatitis C virus positive, white blood cells < 2000 cells/mm3, platelets < 75,000 cells/mm3 and malignancy.InterventionGroup A: basiliximab (20 mg D0 and D4). Group B: thymoglobulin (3 mg/kg total). Maintenance immunosuppression: tacrolimus, mycophenolate mofetil, and steroids.Main Outcome MeasuresBiopsy-proven acute rejection (BPAR), delayed graft function, slow graft function, leukopenia, infections, adverse events, graft loss, estimated glomerular filtration rate, and death within 12 months.Results100 patients (basiliximab, n = 53) (thymoglobulin, n = 47) were included. Donor and recipient characteristics were similar except for longer dialysis (basiliximab), PRA class I (1.2% basiliximab, 4.5% thymoglobulin), HLA match (basiliximab 2.8, thymoglobulin 2.2), and cytomegalovirus status. BPAR rate was basiliximab 3.8% and thymoglobulin 6.4% (P = ns). Delayed graft function (basiliximab 3.8%; thymoglobulin 4.3%), slow graft function, and 12-month leukopenia (basiliximab 11.3%, thymoglobulin 21.3%) were similar between groups (P = ns). There was no difference in infections and adverse events between groups. Patient and graft survival were as follows: basiliximab 98.1% and 92.5%, thymoglobulin 100% and 93.6% (P = ns).ConclusionLow-dose thymoglobulin induction (3 mg/kg) can be used effectively and safely in low-risk kidney transplantation with good results during the first year post-transplant. 相似文献
67.
One of the hallmark characteristics of chronic diabetic wounds is the presence of biofilm‐forming bacteria. Bacteria encapsulated in a biofilm may coexist as a polymicrobial community and communicate with each other through a phenomenon termed quorum sensing (QS). Here, we describe the QS circuits of bacterial species commonly found in chronic diabetic wounds. QS relies on diffusion of signaling molecules and the local concentration changes of these molecules that bacteria experience in wounds. These biochemical signaling pathways play a role not only in biofilm formation and virulence but also in wound healing. They are, therefore, key to understanding the distinctive nature of these infections. While several in vivo and in vitro models exist to study QS in wounds, there has been limited progress in understanding the interplay between QS molecules and host factors that contribute to wound healing. Lastly, we examine the potential of targeting QS for both diagnosis and therapeutic intervention purposes. 相似文献
68.
BackgroundThe surgical treatment of moderate-advanced hallux rigidus is controversial. Cheilectomy is widely used but has recurrence rates of up to 30%. Dorsal oblique metatarsal osteotomy (DOO) has also shown good results, however, there is no study comparing outcomes of the DOO against cheilectomy.MethodsThis was a retrospective propensity score matched study based on registry data from a single tertiary institution. Between 2007 and 2017, all patients who had undergone dorsal cheilectomy or DOO for hallux rigidus were included. Patients with previous foot surgery, revision surgeries, and concomitant surgical procedures were excluded. Clinical outcomes, complication rates, revision rates and patient satisfaction were assessed at 2 years postoperatively.ResultsThere were 44 patients (34 cheilectomy, 10 DOO). After propensity score matching, 17 cheilectomy and all 10 DOO cases were selected for comparison. Patients in both groups had a significant improvement in visual analogue pain scores (VAS) and AOFAS 1st toe scores 2-years post-operatively (P < 0.001) with high levels of post-operative satisfaction (85.1%). Overall there were no statistically significant differences in post-operative scores, improvement in scores, complication rates, revision rates, and levels of patient satisfaction between groups.ConclusionsBoth the DOO and cheilectomy give similarly good outcomes for moderate-advanced hallux rigidus. Further studies are needed to elucidate differences in indications for each procedure. 相似文献
69.
Kapp Judith A.; Pierce Carl W.; Webb David R.; Devens Bruce; Godfrey Wayne; Fukuse Satoshi; Engleman Edgar; Lake Jeffrey P.; Magnani John I.; Maiti Pradip K.; Sehon Alec 《International immunology》1995,7(8):1319-1330
Although reliable antibodies are available that distinguishhuman suppressor T (Ts) cells from CTL and other T cells, feware available for murine Ts cells. We have developed a mAb (984D4.6.5)that, in the presence of complement, depletes alloantigen-specificTs cells but not CTL. This antibody recognizes activated TTscells but not their precursors. In these studies, flow cytometricanalysis demonstrates that 984D4.6.5 reacts with several Tscell hybridomas, cloned Th cell lines and WEHI-3 (a myelomonocytictumor cell line). Reactivity was not detected with BW5147, Thcell hybridomas, cloned Th cells, CTL lines and hybridomas,B cell lines, thymocytes, splenocytes, bone marrow cells nora variety of tumor cells. Among 984D4.6.5 positive lines, expressionis heterogeneous and the number of cells expressing high levelsof the epitope is increased when the hybridomas are maintainedat a relatively high cell density. Neuriminidase and pronasedeplete the epitope recognized by mAb 984D4.6.5. Protein synthesisand glycosylation inhibitors also reduce expression of thisepitope. These observations suggest that the epitope recognizedby 984D4.6.5 is a carbohydrate linked to a polypeptide. Thisantibody was tested by ELISA for binding to a large panel ofcarbohydrates and glycollpids coupled to BSA. The only one thatbound 984D4.6.5 was LS tetrasaccharide c (NeuNAc2-6Galpß1-4GIcNAcß1-3GaIß1-4Glc),an O-linked carbohydrate. Comparative analysis shows that boththe sequence and the linkage of these sugars are essential tothe reactivity with the 984D4.6.5 antibody. This epitope isexpressed by a glycoprotein of-200 kDa, as shown by Westernblots. The identity of this glycoprotein remains to be determined,but indirect evidence suggests that it is not CD45. 相似文献
70.